You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 90 No. 5, May 1965 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Squamous Cell Carcinoma Of Oral Cavity

Intra-Arterial Infusion With Fluorouracil and Idoxuridine

R. O. JOHNSON, MD; W. A. KISKEN, MD; A. R. CURRERI, MD

AMA Arch Surg. 1965;90(5):760-763.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE FIVE-year survival of all patients with squamous cell carcinomas of the oral cavity has been reported as less than 50%.1 Moreover, this survival rate drops precipitously with the advanced lesions more than 3 cm in length. This report is concerned with the intermediate results obtained in 28 consecutive cases of this neoplastic disease with treatment completed 12 to 32 months ago. It will also briefly review the recent use of idoxuridine in association with fluorouracil as an adjunct to radiation therapy.

Materials and Methods

Twenty-eight patients were accepted consecutively for intra-arterial infusion with fluorouracil and subsequent radiotherapy according to the following criteria: (1) biopsy proof of squamous cell carcinoma of the tongue, tonsil, buccal mucosa, alveolar ridge, floor of the mouth, and oropharynx, (2) advanced disease with poor prognosis for survival with conventional therapy, (3) no prior therapy by surgery or radiation, and (4) an adequate infusion demonstrated . . . [Full Text PDF of this Article]


Author Affiliations



MADISON, WIS

From the Division of Clinical Oncology and Department of Surgery, University of Wisconsin Medical Center. Assistant Professor of Surgery and Clinical Oncology (Dr. Johnson); Instructor in Surgery (Dr. Kisken); Director, Division of Clinical Oncology and Professor of Surgery (Dr. Curreri).


Footnotes



Read before the 72nd Annual Session of the Western Surgical Association, Colorado Springs, Colo, Nov 19-21, 1964.

Reprint requests to University of Wisconsin Medical Center, Madison, Wis 53706 (Dr. Johnson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1965 American Medical Association. All Rights Reserved.